Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer

Mohamad Elbaz, Dinesh Ahirwar, Janani Ravi, Mohd W. Nasser, Ramesh K. Ganju

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Breast cancer is the second leading cause of cancer deaths among women. Cannabinoid receptor 2 (CNR2 or CB2) is an integral part of the endocannabinoid system. Although CNR2 is highly expressed in the breast cancer tissues as well as breast cancer cell lines, its functional role in breast tumorigenesis is not well understood. We observed that estrogen receptor-a negative (ERa-) breast cancer cells highly express epidermal growth factor receptor (EGFR) as well as insulin-like growth factor-I receptor (IGF-IR). We also observed IGF-IR upregulation in ERa+ breast cancer cells. In addition, we found that higher CNR2 expression correlates with better recurrence free survival in ERa- and ERa+ breast cancer patients. Therefore, we analyzed the role of CNR2 specific agonist (JWH-015) on EGF and/ or IGF-I-induced tumorigenic events in ERa- and ERa+ breast cancers. Our studies showed that CNR2 activation inhibited EGF and IGF-I-induced migration and invasion of ERa+ and ERa- breast cancer cells. At the molecular level, JWH-015 inhibited EGFR and IGF-IR activation and their downstream targets STAT3, AKT, ERK, NFkB and matrix metalloproteinases (MMPs). In vivo studies showed that JWH-015 significantly reduced breast cancer growth in ERa+ and ERa- breast cancer mouse models. Furthermore, we found that the tumors derived from JWH-015-treated mice showed reduced activation of EGFR and IGF-IR and their downstream targets. In conclusion, we show that CNR2 activation suppresses breast cancer through novel mechanisms by inhibiting EGF/EGFR and IGF-I/IGF-IR signaling axes.

Original languageEnglish (US)
Pages (from-to)29668-29678
Number of pages11
JournalOncotarget
Volume8
Issue number18
DOIs
StatePublished - Jan 1 2017

Fingerprint

Cannabinoid Receptors
IGF Type 1 Receptor
Insulin-Like Growth Factor I
Epidermal Growth Factor Receptor
Epidermal Growth Factor
Breast Neoplasms
Endocannabinoids
Matrix Metalloproteinases
Estrogen Receptors
Cause of Death
Neoplasms
Carcinogenesis
Breast
Up-Regulation

Keywords

  • CNR2
  • EGFR
  • IGF-IR

ASJC Scopus subject areas

  • Oncology

Cite this

Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer. / Elbaz, Mohamad; Ahirwar, Dinesh; Ravi, Janani; Nasser, Mohd W.; Ganju, Ramesh K.

In: Oncotarget, Vol. 8, No. 18, 01.01.2017, p. 29668-29678.

Research output: Contribution to journalArticle

Elbaz, Mohamad ; Ahirwar, Dinesh ; Ravi, Janani ; Nasser, Mohd W. ; Ganju, Ramesh K. / Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer. In: Oncotarget. 2017 ; Vol. 8, No. 18. pp. 29668-29678.
@article{192c174eee954c7aaa2cdf596ab95dfe,
title = "Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer",
abstract = "Breast cancer is the second leading cause of cancer deaths among women. Cannabinoid receptor 2 (CNR2 or CB2) is an integral part of the endocannabinoid system. Although CNR2 is highly expressed in the breast cancer tissues as well as breast cancer cell lines, its functional role in breast tumorigenesis is not well understood. We observed that estrogen receptor-a negative (ERa-) breast cancer cells highly express epidermal growth factor receptor (EGFR) as well as insulin-like growth factor-I receptor (IGF-IR). We also observed IGF-IR upregulation in ERa+ breast cancer cells. In addition, we found that higher CNR2 expression correlates with better recurrence free survival in ERa- and ERa+ breast cancer patients. Therefore, we analyzed the role of CNR2 specific agonist (JWH-015) on EGF and/ or IGF-I-induced tumorigenic events in ERa- and ERa+ breast cancers. Our studies showed that CNR2 activation inhibited EGF and IGF-I-induced migration and invasion of ERa+ and ERa- breast cancer cells. At the molecular level, JWH-015 inhibited EGFR and IGF-IR activation and their downstream targets STAT3, AKT, ERK, NFkB and matrix metalloproteinases (MMPs). In vivo studies showed that JWH-015 significantly reduced breast cancer growth in ERa+ and ERa- breast cancer mouse models. Furthermore, we found that the tumors derived from JWH-015-treated mice showed reduced activation of EGFR and IGF-IR and their downstream targets. In conclusion, we show that CNR2 activation suppresses breast cancer through novel mechanisms by inhibiting EGF/EGFR and IGF-I/IGF-IR signaling axes.",
keywords = "CNR2, EGFR, IGF-IR",
author = "Mohamad Elbaz and Dinesh Ahirwar and Janani Ravi and Nasser, {Mohd W.} and Ganju, {Ramesh K.}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.9408",
language = "English (US)",
volume = "8",
pages = "29668--29678",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "18",

}

TY - JOUR

T1 - Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer

AU - Elbaz, Mohamad

AU - Ahirwar, Dinesh

AU - Ravi, Janani

AU - Nasser, Mohd W.

AU - Ganju, Ramesh K.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Breast cancer is the second leading cause of cancer deaths among women. Cannabinoid receptor 2 (CNR2 or CB2) is an integral part of the endocannabinoid system. Although CNR2 is highly expressed in the breast cancer tissues as well as breast cancer cell lines, its functional role in breast tumorigenesis is not well understood. We observed that estrogen receptor-a negative (ERa-) breast cancer cells highly express epidermal growth factor receptor (EGFR) as well as insulin-like growth factor-I receptor (IGF-IR). We also observed IGF-IR upregulation in ERa+ breast cancer cells. In addition, we found that higher CNR2 expression correlates with better recurrence free survival in ERa- and ERa+ breast cancer patients. Therefore, we analyzed the role of CNR2 specific agonist (JWH-015) on EGF and/ or IGF-I-induced tumorigenic events in ERa- and ERa+ breast cancers. Our studies showed that CNR2 activation inhibited EGF and IGF-I-induced migration and invasion of ERa+ and ERa- breast cancer cells. At the molecular level, JWH-015 inhibited EGFR and IGF-IR activation and their downstream targets STAT3, AKT, ERK, NFkB and matrix metalloproteinases (MMPs). In vivo studies showed that JWH-015 significantly reduced breast cancer growth in ERa+ and ERa- breast cancer mouse models. Furthermore, we found that the tumors derived from JWH-015-treated mice showed reduced activation of EGFR and IGF-IR and their downstream targets. In conclusion, we show that CNR2 activation suppresses breast cancer through novel mechanisms by inhibiting EGF/EGFR and IGF-I/IGF-IR signaling axes.

AB - Breast cancer is the second leading cause of cancer deaths among women. Cannabinoid receptor 2 (CNR2 or CB2) is an integral part of the endocannabinoid system. Although CNR2 is highly expressed in the breast cancer tissues as well as breast cancer cell lines, its functional role in breast tumorigenesis is not well understood. We observed that estrogen receptor-a negative (ERa-) breast cancer cells highly express epidermal growth factor receptor (EGFR) as well as insulin-like growth factor-I receptor (IGF-IR). We also observed IGF-IR upregulation in ERa+ breast cancer cells. In addition, we found that higher CNR2 expression correlates with better recurrence free survival in ERa- and ERa+ breast cancer patients. Therefore, we analyzed the role of CNR2 specific agonist (JWH-015) on EGF and/ or IGF-I-induced tumorigenic events in ERa- and ERa+ breast cancers. Our studies showed that CNR2 activation inhibited EGF and IGF-I-induced migration and invasion of ERa+ and ERa- breast cancer cells. At the molecular level, JWH-015 inhibited EGFR and IGF-IR activation and their downstream targets STAT3, AKT, ERK, NFkB and matrix metalloproteinases (MMPs). In vivo studies showed that JWH-015 significantly reduced breast cancer growth in ERa+ and ERa- breast cancer mouse models. Furthermore, we found that the tumors derived from JWH-015-treated mice showed reduced activation of EGFR and IGF-IR and their downstream targets. In conclusion, we show that CNR2 activation suppresses breast cancer through novel mechanisms by inhibiting EGF/EGFR and IGF-I/IGF-IR signaling axes.

KW - CNR2

KW - EGFR

KW - IGF-IR

UR - http://www.scopus.com/inward/record.url?scp=85018967943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018967943&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9408

DO - 10.18632/oncotarget.9408

M3 - Article

C2 - 27213582

AN - SCOPUS:85018967943

VL - 8

SP - 29668

EP - 29678

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 18

ER -